Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER

EZH2 accompanies prostate cancer progression

Nature Cell Biology volume 23, pages 934–936 (2021)Cite this article

Subjects

Enhancer of zeste homolog 2 (EZH2) has been shown to promote development of castration-resistant prostate cancer (CRPC) through various mechanisms. A new study now shows that a phosphorylated EZH2 interacts with the androgen receptor (AR) and reprograms AR transcriptional activity to facilitate transition of CRPC into a lineage infidelity state.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: EZH2 plays a multifaceted role in prostate cancer progression.

References

  1. Quintanal-Villalonga, Á. et al. Nat. Rev. Clin. Oncol. 17, 360–371 (2020).

    Article  Google Scholar 

  2. Labrecque, M. P. et al. J. Clin. Invest. 129, 4492–4505 (2019).

    Article  Google Scholar 

  3. Ku, S. Y. et al. Science 355, 78–83 (2017).

    Article  CAS  Google Scholar 

  4. Dardenne, E. et al. Cancer Cell 30, 563–577 (2016).

    Article  CAS  Google Scholar 

  5. Berger, A. et al. J. Clin. Invest. 129, 3924–3940 (2019).

    Article  Google Scholar 

  6. Davies, A. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-021-00743-5 (2021).

  7. Varambally, S. et al. Nature 419, 624–629 (2002).

    Article  CAS  Google Scholar 

  8. Zhao, J. C. et al. Genome Res. 22, 322–331 (2012).

    Article  CAS  Google Scholar 

  9. Xu, K. et al. Science 338, 1465–1469 (2012).

    Article  CAS  Google Scholar 

  10. Kim, J. et al. Cell Rep. 25, 2808–2820.e4 (2018).

    Article  CAS  Google Scholar 

  11. Kleb, B. et al. Epigenetics 11, 184–193 (2016).

    Article  Google Scholar 

  12. Chen, S. et al. Nat. Cell Biol. 12, 1108–1114 (2010).

    Article  CAS  Google Scholar 

  13. Wan, L. et al. Mol. Cell 69, 279–291.e5 (2018).

    Article  CAS  Google Scholar 

  14. Bai, Y. et al. J. Biol. Chem. 294, 9911–9923 (2019).

    Article  CAS  Google Scholar 

  15. Puca, L. et al. Nat. Commun. 9, 2404–2413 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Washington, Seattle, WA, USA

    Li Xin

  2. Institute of Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA

    Li Xin

Authors
  1. Li Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Xin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xin, L. EZH2 accompanies prostate cancer progression. Nat Cell Biol 23, 934–936 (2021). https://doi.org/10.1038/s41556-021-00744-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41556-021-00744-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing